Population Pharmacokinetic Meta-Analysis of Denosumab in Healthy Subjects and Postmenopausal Women with Osteopenia or Osteoporosis

• Published in: Clinical pharmacokinetics Vol. 50; no. 12; pp. 793 - 807
• Main Authors: Sutjandra, Liviawati, Rodriguez, Rachelle D., Doshi, Sameer, Ma, Mark, Peterson, Mark C., Jang, Graham R., Chow, Andrew T., Pérez-Ruixo, Juan José
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.12.2011; Adis International; Wolters Kluwer Health, Inc; Springer Nature B.V
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal - blood; Antibodies, Monoclonal - pharmacokinetics; Antibodies, Monoclonal, Humanized; Biological and medical sciences; Bone Density Conservation Agents - blood; Bone Density Conservation Agents - pharmacokinetics; Bone Diseases, Metabolic - blood; Bone Diseases, Metabolic - drug therapy; Denosumab; Diagnosis; Diseases of the osteoarticular system; Drug therapy; Female; General pharmacology; Health aspects; Humans; Internal Medicine; Medical sciences; Medicine; Medicine & Public Health; Middle Aged; Models, Biological; Original Research Article; Osteopenia; Osteoporosis; Osteoporosis - blood; Osteoporosis - drug therapy; Osteoporosis. Osteomalacia. Paget disease; Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions; Pharmacology. Drug treatments; Pharmacology/Toxicology; Pharmacotherapy; Postmenopausal women; Postmenopause - blood; RANK Ligand - antagonists & inhibitors; Young Adult; Spain; Omalizumab; Ustekinumab; Denosumab; Stochastic Approximation Expectation Maximization; Conditional Weighted Residual; Human; Population pharmacokinetics; Healthy subject; Menopause; Diseases of the osteoarticular system; Monoclonal antibody; Metaanalysis; Immunomodulator; Osteoporosis; Postmenopause; Adult; Female; Woman; Osteopenia
• ISSN: 0312-5963; 1179-1926; 1179-1926
• DOI: 10.2165/11594240-000000000-00000

Background and Objective: Inhibition of the receptor activator of nuclear factor k-B ligand (RANKL) is a therapeutic target for treatment of bone disorders associated with increased bone resorption, such as osteoporosis. The objective of this analysis was to characterize the population pharmacokinet...